Rotenone in Drug-Resistant Epilepsy Models: Powerful Tool or Problematic Paradigm?

Area of Science:

• Neuroscience
• Pharmacology
• Epilepsy Research

Background:

• Drug-resistant epilepsy (DRE) presents significant treatment challenges.
• Existing models often lack comprehensive clinical feature replication.
• Mitochondrial dysfunction and neuroinflammation are implicated in DRE pathogenesis.

Purpose of the Study:

• To evaluate the rotenone adjuvant pentylenetetrazol (PTZ)-kindling paradigm as a model for DRE.
• To assess its construct, face, and predictive validity compared to traditional models.
• To determine its suitability for testing novel mechanism-based therapies.

Main Methods:

• Combined rotenone (mitochondrial complex I inhibitor) with PTZ or corneal kindling.
• Administered repeated subconvulsive doses of PTZ to induce epileptogenesis.
• Assessed seizure susceptibility, neuroinflammation, oxidative stress, and drug penetration.

Main Results:

• The model replicated key DRE features: pharmacoresistance, neuroinflammation, and oxidative stress.
• Rotenone potentiated PTZ sensitivity, affecting blood-brain barrier integrity and transporter expression.
• The paradigm showed construct, face, and predictive validity, including comorbidities and spontaneous seizures.

Conclusions:

• The rotenone adjuvant PTZ-kindling model is a promising translational platform for DRE research.
• It offers improved clinical relevance for evaluating therapies targeting mitochondrial dysfunction, GABAergic imbalance, and inflammation.
• Limitations include systemic toxicity, mortality, and inter-animal variability that require further investigation.